The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...

Abstract: Background and Aim: Continuous subcutaneous insulin infusion (CSII) with sensor-augmented pumps is widely used in the treatment of type 1 diabetes. Patterning of glucose profiles using ...

Abstract: Intravenous (IV) therapy is a critical component of modern healthcare, yet traditional IV systems are prone to human errors, manual adjustments, and limited monitoring capabilities, which ...

For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole while a clear bag slowly empties into a vein. A new generation of ...

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)-- InfuSystem Holdings, Inc. (INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable ...